2020 western region candidates
Candidates are listed alphabetically by last name.
Professor, University of Ottawa, Canada
Daniel Figeys is a professor in the Department of Biochemistry, Microbiology and Immunology, at the University of Ottawa. He is a Distinguished Research Chair at the University of Ottawa, Senior Fellow in the Canadian Foundation for Advanced Research (CIFAR) and received the Chinese Academy of Sciences President’s International Fellowship Initiative (PIFI). He is the founding co-director of the Shanghai Institute of Materia Medica-University of Ottawa Joint Research Center in Systems and Personalized Pharmacology. He was the founding Director of the Ottawa Institute of Systems Biology and directed the institute for 10 years. Daniel is co-founder of MedBiome Inc, a company focused on targeting the microbiome to improve human health. Prior to joining the University of Ottawa, Daniel was Senior Vice President Systems at MDS-Proteomics. Daniel obtained a B.Sc. and M.Sc. in chemistry from the Université de Montréal and a Ph.D. from the University of Alberta. He did his postdoctoral studies at the University of Washington. He has published over 190 papers cited over 15,000 times. Within HUPO, Daniel serves as co-director of the HUPO Food and Nutrition Initiative. Daniel also participated in the HUPO mentoring activities during the congress and would like to keep promoting different career paths and professional development. Daniel would also like to further develop the microbiome and health aspect within HUPO.
Professor, University of Nebraska Medical Center, USA
I would like to continue serving on the HUPO Council in order to directly support HUPO's efforts to study human development and disease through proteomic technologies. Throughout my career, I have had the opportunity to work at the interface of proteomics, regenerative medicine and developmental biology. Our laboratory develops and applies innovative technologies, bioinformatics tools, and methodologies to transform our understanding of cell surface proteins and glycans and answer outstanding questions in stem cell biology and cardiac pathology. Beyond our own research program, I am the Director of the CardiOmics Program at the University of Nebraska Medical Center where I am actively involved in engaging the biomedical community, promoting a broad range of molecular-level research, from biomarker discovery and validation to mechanistic studies, and providing educational opportunities regarding mass spectrometry analyses of biological molecules. The HUPO organization is well-positioned to enhance the continued expansion, standardization, and integration of proteomics into biomedical research. I would like to contribute to this goal, especially through participating in initiatives supporting standardizations in protein characterizations and phenotypic evaluation and the free and rapid exchange of data and analytical workflows. I am currently Co-Chair of the HUPO B/D HPP Cardiovascular Initiative and actively participate in the annual HUPO World Congresses. I am also on the Board of Directors for US HUPO.
Professor, University of Michigan, USA
Alexey Nesvizhskii received his Ph.D. from the University of Washington in 2001 for his studies on theoretical solid state physics. After joining the laboratory of Ruedi Aebersold at the Institute for Systems Biology in Seattle, his research interests focused on the emerging fields of mass spectrometry-based proteomics and proteome bioinformatics. He established his own laboratory (www.nesvilab.org) in 2005 at the University of Michigan, Ann Arbor, where he is Professor in the Departments of Pathology and Computational Medicine & Bioinformatics. Dr. Nesvizhskii’s research contributions include the development of concepts and computational methods implemented in many widely used bioinformatics tools, including PeptideProphet and ProteinProtein, iProphet, CRAPome, SAINT, DIA-Umpire, MSFragger, and Philosopher. His lab actively collaborates with technology developers, biologists, and clinical scientists on a variety of projects, including reconstruction and analysis of protein-protein interaction networks, post-translational modification profiling, integrative modeling of multi-omics data to reconstruct targetable pathways in cancer, and biomarker discovery. He currently serves on the Board of Directors for the American Society of Mass Spectrometry (ASMS), US HUPO, and on the Scientific Advisory Board for Swiss Institute of Bioinformatics. At the University of Michigan (UM), Dr. Nesvizhskii directs the NCI-funded T32 Proteome Informatics of Cancer Training Program and the Proteogenomics Data Analysis Center (UM-PGDAC; part of the Clinical Proteomic Tumor Analysis Consortium initiative). He also Directs the Proteomics Resource Facility which provides cutting-edge proteomics capabilities to UM investigators, and the Michigan Compound Identification Development Cores project which focuses on the identification of previously unknown metabolites. As an enthusiastic educator, Dr. Nesvizhskii teaches graduate-level courses in the area of bioinformatics, proteomics, and systems biology. In addition, he developed and taught multiple internationally recognized hands-on workshops and tutorials.
Senior Investigator, Laboratory of Immune System Biology, NIAID, NIH, USA
I have served on the HUPO Council from 2017 to 2019 and I would like to ask for the support from the HUPO community to continue doing so.
I have been working in the area of proteomics and mass spectrometry throughout my professional career. During my graduate studies in Switzerland, I utilized mass spectrometry to study the unusual post-translational modification, the C-mannosylation of the tryptophan residues in proteins. As a postdoc in the US, I worked on PTMs in cell signaling, mapping and determining the site occupancy levels for the O-fucosylation and O-glucosylation sites in Notch receptors and conducting the large-scale studies of the tyrosine phosphorylation dynamics in the protein signaling networks. Currently, I lead the Functional Cellular Networks Section at the Laboratory of Immune System Biology at NIAID, NIH, characterizing the changes of protein abundance and PTM status in the innate immune signaling with a goal to be able to create robust, accurate, and predictive mathematical network models.
After joining HUPO, I realized that my professional experience, interests and goals were exceptionally well aligned with these of the HUPO. I enthusiastically support the Organization’s mission and I contribute towards it with my energy and skills. As a Council member I was able to promote HUPO’s mission locally and internationally through intense networking and I hope to continue this work if elected. I am currently the Chair of the Nominations and Elections Committee and I have served as member of the Awards Committee. I have co-organized the US HUPO Annual Meeting in March 2019. I am especially interested in communicating and reinforcing the message that, because proteins constitute the functional cellular machinery, the importance of proteomics as the crucial step beyond gene expression studies should continue to be emphasized to the scientists of all fields! I plan to continue being active in Congress organization and promote proteomics in systems biology.
At the community service level - I am particularly focused on mentoring young scientists who will shape the future of proteomics.
Professor, Canada Research Chair,University of British Columbia, Canada
Chris Overall has been active in HUPO for more than a decade and since 2014 was elected to HUPO Council. I now sit on the HUPO Executive Committee as Treasurer, and since 2019 I was elected Chair of the C-HPP after serving as Co-Chair from 2015. I have been leading the NeXt-50 Missing Protein Challenge, and am Editor of the 3rd to 8th Journal of Proteome Research Special Issues on the HPP. I am an Associate Editor of JPR since 2015 and was also an Editor of mSystems 2015-1019.
Dr Overall was appointed a Tier 1 Canada Research Chair in Protease Proteomics and Systems Biology (2001) and a Senior Fellow of the Freiburg Institute of Advanced Studies, Universität Freiburg, Germany (2010–2013), where he is an Honorary Professor (2014–). I was inducted as a fellow into the Royal Society of Canada in 2018. I published my first proteomics paper in 2004 in PNAS on the application of ICAT for membrane protein shedding by proteases leading to substrate discovery, thus initiating the field of degradomics. My lab has continued to pioneer innovative quantitative proteomic techniques and polymers-for-proteomics to enrich and identify proteolysis products in vivo, enabling the identification of protein natural N and C termini, proteolytic cleaved neo-N- and neo-C-termini, proteolytic proteoforms, and thereby understanding of the roles of proteases in vivo. Presently, my entire lab is using our degradomics platform to discover new substrates and pathobiological roles for the SARS CoV-2 3CLpro and PLpro proteases in COVID-19.
He is an influential scientist (h-index of 90) with >30,000 citations from 281 papers, including 28 high-impact Nature (1), Science (2), Cell and daughter journal (25) papers. He has trained 39 PDFs and graduated 14 Ph.D. and 5 M.Sc. students, with 6 now Full Professors, 3 Associate Professors, and 8 Assistant Professors.
Jennifer Van Eyk
Prof of Medicine, Director ACBRI and Precision Biomarker Labs, Cedars-Sinai Medical Center, USA
1. I am committed to facilitating the application of proteomics across all areas of science. This includes i) strengthening the interactions within proteomic community ii) facilitating interactions between proteomics and the broader biological and clinical scientific community, iii) support of technology innovation and implementation of standards and iv) facilitating the development of proteomic leaders and early career researchers.
2. I strongly support volunteering as an obligation and a joy. Since an assistant professor, I volunteer for work within my institution and for societies within proteomics community and my biological clinical areas of interest. I have extensive experience in leadership at the society levels from HUPO, American Heart Association, Mass Spectrometry Applications to the Clinical Lab (MSACL) and the International Society of Heart research.
3. I am a builder and create opportunities for those around me. The growth of the B/D-HPP initiative from when I become chair (and then co-chair) with additional initiatives, a more defined vision, the development of the early career research committed, and its and participation in the annual meeting.
4. I am excellent mentor. I was first PhD to obtain the David Levine excellence in mentoring awards in Dept Medicine at Johns Hopkins University. I take great pride in the obligation to nurture and mentor the younger generation to become future leaders of organizations like HUPO.
5. I am an innovator and know how to build resources and infrastructure for the future. This is seen the development of the first Functional Genomics and Translational Biology Council at the American Heart Association which I chaired. It grew from having 0 membership to over 700 in less than 3 years and growth of ECR at HUPO (from 0 to something remarkable).
6. Importantly, I know how to build bridges between ideas, people and scientific disciplines. I think outside the box to enable success.